I think Silence Therapeutics ( SLN ) is currently at an interesting stage. I see it as a focused, clinical-stage RNAi-focused drug development company, but its valuation continues to reflect historical execution concerns and general small-cap biotech exhaustion more soI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My approach is ...